Philips Expands Technology Leadership In Image-Guided Therapy With Acquisition Of CardioProlific Inc.

Royal Philips, a global leader in health technology, recently announced the acquisition of CardioProlific Inc., a US-based, privately-held company that is developing catheter-based thrombectomy approaches to treat peripheral vascular disease. Financial details of the transaction will not be disclosed.

CardioProlific’s technologies are complementary to Philips’ portfolio of image-guided therapy devices and to the portfolio of The Spectranetrics Corporation, which Philips recently has agreed to acquire. The acquisition of CardioProlific underpins Philips’ aim to develop new solutions for clinicians to decide, guide, treat and confirm the appropriate therapy for cardiac and peripheral vascular disease.

“The acquisition of CardioProlific will further strengthen our innovation pipeline of catheter-based therapy devices,” said Bert van Meurs, Business Leader Image Guided Therapy at Philips. “We are convinced that the development of CardioProlific’s differentiated thrombectomy technologies, combined with our suite of image-guided therapy solutions, will help our customers drive the procedure innovation for the treatment of peripheral vascular disease.”

Philips’ image-guided therapy portfolio today comprises interventional imaging systems, planning and navigation software, interventional devices - including catheters for diagnosis and therapy - and a broad range of services, all aimed at helping clinicians to deliver more efficient and effective care to improve the lives of the patients they treat.

About Royal Philips
Royal Philips is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 70,000 employees with sales and services in more than 100 countries. For more information, visit www.philips.com/newscenter.

Additional Information
The tender offer described in this communication (the “Offer”) has not yet commenced, and this communication is neither an offer to purchase nor a solicitation of an offer to sell any shares of the common stock of Spectranetics or any other securities. On the commencement date of the Offer, a tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and related documents, will be filed with the United States Securities and Exchange Commission (the “SEC”) by Philips and a Solicitation/Recommendation Statement on Schedule 14D-9 will be filed with the SEC by Spectranetics. The offer to purchase shares of Spectranetics common stock will only be made pursuant to the offer to purchase, the letter of transmittal and related documents filed as a part of the Schedule To. Investors And Security Holders Are Urged To Read Both The Tender Offer Statement And The Solicitation/ Recommendation Statement Regarding The Offer, As They May Be Amended From Time To Time, When They Become Available Because They Will Contain Important Information. The tender offer statement will be filed with the SEC by HealthTech Merger Sub, Inc., a wholly owned subsidiary of Philips Holding USA Inc., which is a wholly owned subsidiary of Royal Philips, and the solicitation/recommendation statement will be filed with the SEC by Spectranetics. Investors and security holders may obtain a free copy of these statements (when available) and other documents filed with the SEC at the website maintained by the SEC at www.sec.gov or by directing such requests to the Information Agent for the Offer, which will be named in the tender offer statement.